The effect of Rosiglitazone in the treatment of depression

Rosiglitazone as an adjunctive therapy in the treatment of patients with moderate to severe major depressive disorder: A randomized double-blind placebo-controlled clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20090117001556N152

Enrollment

Registered

2023-06-20

Start date

2023-07-23

Completion date

Unknown

Last updated

2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major depressive disorder. Major depressive disorder, single episode

Interventions

Intervention 1: Control group: Sertraline (100 mg/day) and placebo for six weeks. Intervention 2: Intervention group: Sertraline (100 mg/day) and Rosiglitazone (2 mg, twice a day) for six weeks.

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Diagnosed with major depressive disorder (MDD) based on DSM5 Depression severity should be above 22 according to the Hamilton Depression Scale Age between 18-60

Exclusion criteria

Exclusion criteria: Psychotic patients Diagnosis of any disturbances in other axes The use of psychoactive drugs The use of antidepressants in the last one month or ECT in the last two months History of cardiovascular disease (EKG can be taken, and if there is a problem in the function of heart, the patient is excluded from the study) Thyroid problems Pregnant and lactating women

Design outcomes

Primary

Measure	Time frame
Severity of depression. Timepoint: Weeks: 0-2-4-6. Method of measurement: by Hamiltion Depression Rating Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Shahin Akhondzadeh

Tehran University of Medical Sciences

s.akhond@sina.tums.ac.ir+98 21 5541 2222

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026